The Foundation continues to earn world-wide recognition for our success developing new CF treatments, advancing quality care and furthering the search for a cure.

This summer we continued to achieve progress in key areas. Here are some highlights:

• Phase 3 VX-770 trials are underway, including studies of the treatment in patients with the G551D mutation, the F508del mutation and patients as young as six years of age. In addition, the VX-809 Phase 2 trial is now recruiting patients and, as you may remember, this drug could potentially be effective in over 90% of the CF patients that have the F508del mutation.
• Two additional Phase 3 trials directed toward treating the basic defect are underway. PTC Therapeutics just launched its Phase 3 trial of Ataluren (formerly known as PTC124). Inspire Pharmaceuticals has nearly completed enrollment of its Phase 3 trial of denufosol. Inspire is aiming for FDA approval of this therapy in 2011.
• Nearly 250 patients have received help with their drug co-pays through the new CF Patient Assistance Foundation. The fact that over a quarter of our patients skip some of their treatment because of financial concerns underscores the need for this important, industry-supported program.
• The Foundation received its second 4-star rating from Charity Navigator for exceptional fiscal management. This recognition is a tribute to the entire Foundation and its focus on innovation and efficiency.

In addition, we estimate that over 13 Phase 3 trials may be completed by 2013. When you consider that in the past 15 years only two drugs have been approved by the FDA, we must be excited by our progress.

Our greatest achievement by far is that those with CF are living longer and healthier lives.

Sincerely yours,

Robert J. Beall, Ph.D.
President and CEO
Cystic Fibrosis Foundation